Treatment for Depression

Phase-Based Progress Estimates
The University of Pittsburgh, Department of Psychiatry, Pittsburgh, PA
Depression+1 More
18 - 65
All Sexes
What conditions do you have?

Study Summary

This trial will study whether theta burst stimulation, a type of magnetic brain stimulation, can help reduce the severity of depression symptoms. A subset of participants will also receive positive affect training. This treatment is used to treat Depression. No patients in this trial will receive a placebo. This is a double-blind study, which means that neither the patients nor the researchers will know which patients are receiving the treatment and which are not.

Eligible Conditions

  • Depression

Treatment Effectiveness

Study Objectives

1 Primary · 0 Secondary · Reporting Duration: up to 1 year

up to 1 year
depression severity

Trial Safety

Trial Design

0 Treatment Group

30 Total Participants · 0 Treatment Group

Primary Treatment: Treatment · No Placebo Group · N/A

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: up to 1 year
Closest Location: The University of Pittsburgh, Department of Psychiatry · Pittsburgh, PA
Photo of Pittsburgh 1Photo of Pittsburgh 2Photo of Pittsburgh 3
2022First Recorded Clinical Trial
2 TrialsResearching Depression
1 CompletedClinical Trials

Who is running the clinical trial?

Erika ForbesLead Sponsor
2 Previous Clinical Trials
304 Total Patients Enrolled
2 Trials studying Depression
304 Patients Enrolled for Depression
Erika E Forbes, Ph.DPrincipal InvestigatorUniversity of Pittsburgh

Eligibility Criteria

Age 18 - 65 · All Participants · 1 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.